TCR (T-cell receptor)

In one sentence

A conventional alpha-beta T-cell receptor recognizes a peptide together with the human leukocyte antigen molecule displaying it.

The intuition

The reader inspects both the fragment and its holder. Human leukocyte antigen (HLA) holds the peptide in a groove; the T-cell receptor (TCR) contacts that combined surface. The analogy does not mean every reader has exactly one possible match.

How it works

Most conventional T cells use alpha and beta receptor chains. Developing cells rearrange gene segments to create diversity, then undergo selection. The receptor works with CD3 signaling proteins and often a CD4 or CD8 co-receptor.

One receptor can recognize more than one peptide–HLA complex. This cross-reactivity is biologically useful but also matters when testing engineered receptors for healthy-tissue risk. Binding, activation and killing are separate outcomes.

A clone contains descendants of a T cell, generally sharing its receptor. A repertoire is the collection of sampled receptors. Sequencing can identify sequences and their measured abundance. It does not directly reveal the antigen every receptor recognizes. Adult thymic output declines but persists, while existing cells can maintain themselves through proliferation.

Why it matters in cancer

Vaccines can expand existing antigen-reactive clones. Engineered TCR therapy installs selected receptors in cells. A sequence discovered after vaccination is a candidate for follow-up, rather than an automatically usable therapeutic product.

Worked example

A fictional clone becomes more frequent after vaccination. A peptide-response assay strengthens a specificity claim; testing recognition of appropriately presenting tumor cells strengthens a different claim. Neither an abundance change nor a single binding assay establishes clinical benefit.

Common confusions

The peptide sits in the HLA groove, not in a separate TCR peptide pocket.
One receptor is not necessarily limited to one peptide.
A vaccine does not normally rewrite the receptors of mature responding T cells.

Sources and scope

Source check: October 8, 2026. This is a mechanism explanation, not a treatment recommendation. Expert and learner review remain pending.